Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
companyunderground
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Why Estimates of Future Revenues for Obesity Drugs Are Likely Off the Mark
Why Estimates of Future Revenues for Obesity Drugs Are Likely Off the Mark
Why Estimates of Future Revenues for Obesity Drugs Are Likely Off the Mark
Submitted by
admin
on October 19, 2009 - 6:43pm
Source:
BNET Pharma
News Tags:
obesity
Qnexa
Vivus
Arena Pharmaceuticals
Orexigen
Contrave
Headline:
Why Estimates of Future Revenues for Obesity Drugs Are Likely Off the Mark
Do Not Allow Advertisers to Use My Personal information
